CORAL SPRINGS, FL--(Marketwire - Feb 14, 2013) - "Active HealthCare Companies Watch" for today: Crown Marketing Pharmaceuticals (OTCQB: CWNM), YaFarm Technologies, Inc. (PINKSHEETS: YFRM), GrowLife, Inc. (OTCQB: PHOT) and Bond Laboratories, Inc. (OTCQB: BNLB)
Crown Marketing Pharmaceuticals (OTCQB: CWNM) announced today that Patents for its Controlled Drug Delivery Technology (CDDT) have been approved and registered in South Africa. This is CWNM's second major announcement regarding the approval of new Patents following last week's news it had also secured Patents in Norway. Read the full release with company disclosures at http://www.financialnewsmedia.com/stock-investing-business-investing-news/featured-news.php?id=250
Crown is continuing to secure its worldwide patent rights as it pursues novel applications of its drug delivery technology. CWNM also announced last week on February 7th the company has begun to review positive in vivo test results by examining blood plasma levels in test subjects using Crown's Controlled Drug Delivery Technology (CDDT). A clinical trial was conducted using 300 mg of Dexibuprofren Lysine and found that the blood plasma levels tracked the in vitro test results conducted earlier. The clinical trial appears to validate our belief and claims that because of the controllable diffusion dynamics and our mathematical modeling, we can predict with a high degree of certainty the release kinetics. For more details regarding Crown's CDDT applications, go to http://crowncddt.com/technology/
Stay informed on Crown Marketing developments by getting FREE news alerts & updates delivered directly to your mobile phone by texting STOCK to 545454 from your cellular device or visit http://cwnm.mobi for more details.
YaFarm Technologies, Inc. (PINKSHEETS: YFRM) announced this week that The Integrative Stem Cell Institute (ISCI), a premier provider of point-of-care, stem cell-based therapies, has launched a global physician's network, to connect international patients to local physicians, and to link physicians to opportunities for education, training and collaboration in regenerative medicine.
GrowLife, Inc. (OTCQB: PHOT), a provider of highly effective indoor growing technologies, announced this week that it has engaged Medicus Research, LLC to provide a comprehensive review of worldwide scientific literature on the therapeutic benefits of medical marijuana. Medicus Research is a premier organization engaged in clinical trials across various disciplines and is uniquely staffed to concentrate on early stage botanical drugs and the related published medical literature.
Bond Laboratories, Inc. (OTCQB: BNLB), an international provider of innovative and proprietary nutritional supplements for health conscious consumers marketed primarily through its wholly owned operating division, NDS Nutrition Products ("NDS"), recently announced that the Company is introducing another new, cutting edge product, EvoLean™, to its impressive list of effective diet and weight loss formulations. BNLB is trading up early today at $0.11 on over 2.5 Million shares traded since 10:30am on 2/14/13.
FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com for more details.
DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.
To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For disseminating this release, FNMG expects to be compensated one thousand five hundred dollars for coverage of this news release by a non-affiliated third party company. FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE AND WAS NOT COMPENSATED BY ON OTHER COMPANY INCLUDED HEREIN.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.